Adlai Nortye is an oncology-focused biopharmaceutical company that develops cancer therapeutics through a dual model combining internal drug discovery with in-licensing of clinical-stage candidates from external partners. The company conducts preclinical studies and clinical trials across multiple geographies in North America, Europe, and Asia, leveraging its global clinical development capabilities and molecular expertise. It outsources manufacturing to contract organizations and has no in-house production capacity; commercialization will depend on securing regulatory approvals and establishing partnerships with third-party distributors, as the company currently generates no product revenue and relies on research funding and government grants to support its operations.